Literature DB >> 3740044

Geographic variation in infant loss of maternal measles antibody and in prevalence of rubella antibody.

F L Black, L L Berman, J M Borgoño, R A Capper, A A Carvalho, C Collins, O Glover, Z Hijazi, D L Jacobson, Y L Lee.   

Abstract

Maternal and cord measles and rubella antibodies were compared in 15 populations from Brazil, Ecuador, Chile, India, Jordan, Nigeria, South Africa, Taiwan, and the United States. Review of the literature concerning these countries showed that a higher proportion of children 6-12 months of age responded immunologically to measles vaccine in areas with low per capita product than in wealthier populations. The authors show that this difference reflects differences in maternal antibody titer and differences in efficiency of transport of measles immunity across the placenta. No variation in the half-life of passive measles immunity in the infant was found in comparing three geographic areas. When these biologic factors are fully evaluated, it should be possible to predict the response to be expected from vaccination at any particular age without directly testing the vaccine in children below and above generally recommended ages for vaccination. With regard to rubella, high antibody prevalence rates were found in most of the developing countries, as well as in the United States, and these countries are therefore unlikely to encounter widespread problems with congenital rubella. However, Taiwan, and all of four areas of Brazil have prevalence rates which are no higher than those which pertained in the United States prior to establishment of the rubella immunization program. The authors believe that protection of the infants in these countries is a matter of high priority, but that, if approached hastily, it could exacerbate the problem.

Entities:  

Mesh:

Year:  1986        PMID: 3740044     DOI: 10.1093/oxfordjournals.aje.a114415

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  13 in total

1.  Loss of maternally acquired measles antibodies in well-nourished infants and response to measles vaccination, Peru.

Authors:  A Vaisberg; J O Alvarez; H Hernandez; D Guillen; P Chu; A Colarossi
Journal:  Am J Public Health       Date:  1990-06       Impact factor: 9.308

2.  The modification in measles vaccination age as a consequence of the earlier decline of transplacentally transferred antimeasles antibodies in Turkish infants.

Authors:  D U Altintaş; N Evliyaoğlu; B Kilinç; D I Sen'an; S Güneşer
Journal:  Eur J Epidemiol       Date:  1996-12       Impact factor: 8.082

3.  Measles virus-specific antibody levels in individuals in Argentina who received a one-dose vaccine.

Authors:  Marcelo H Argüelles; Mariana L Orellana; Alejandro A Castello; Guillermo A Villegas; Matilde Masini; Alejandra L Belizan; Silvia González Ayala; Osmar D Vera; Graciela Glikmann
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

Review 4.  Control of rubella and congenital rubella syndrome (CRS) in developing countries, Part 1: Burden of disease from CRS.

Authors:  F T Cutts; S E Robertson; J L Diaz-Ortega; R Samuel
Journal:  Bull World Health Organ       Date:  1997       Impact factor: 9.408

5.  Ideal age for measles vaccination with persisting maternal antibody, human immunodeficiency virus infection and protein-calorie malnutrition.

Authors:  S C Arya
Journal:  Infection       Date:  1993 Jul-Aug       Impact factor: 3.553

6.  Measles vaccination policy.

Authors:  B G Williams; F T Cutts; C Dye
Journal:  Epidemiol Infect       Date:  1995-12       Impact factor: 2.451

7.  A study of maternally derived measles antibody in infants born to naturally infected and vaccinated women.

Authors:  R Brugha; M Ramsay; T Forsey; D Brown
Journal:  Epidemiol Infect       Date:  1996-12       Impact factor: 2.451

8.  Half-life of the maternal IgG1 allotype in infants.

Authors:  H Sarvas; I Seppälä; S Kurikka; R Siegberg; O Mäkelä
Journal:  J Clin Immunol       Date:  1993-03       Impact factor: 8.317

9.  Lack of efficacy of the standard potency Edmonston-Zagreb live, attenuated measles vaccine in African infants.

Authors:  P Kiepiela; H M Coovadia; W E Loening; P Coward; G Botha; J Hugo; P J Becker
Journal:  Bull World Health Organ       Date:  1991       Impact factor: 9.408

10.  Use of a microquantity enzyme immunoassay in a large-scale study of measles, mumps and rubella immunity in Italy.

Authors:  F Condorelli; A Stivala; R Gallo; A Marino; C M Battaglini; A Messina; G Russo; A Castro; G Scalia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.